Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T13:47:06.484Z.
Calculation as of: 2026-10-06T13:47:06.484Z.
Quote observation: 2026-10-06T13:45:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cb51854f5b6e3a7e5b706ce3fddb8e5618a295b9891c132556284ed892856c50
EARNINGS YIELD
N/A
Market Cap
$237.08M
Earnings Yield
N/A
TTM Avg
37.01%
3Y Avg
37.01%
5Y Avg
37.01%
Market Cap
$244.11M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$244.19M
Earnings Yield
N/A
TTM Avg
2.23%
3Y Avg
2.23%
5Y Avg
2.23%
Market Cap
$248.50M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| High Tide Inc. (HITI) | $241.20M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $237.08M | N/A | 37.01% | 37.01% | 37.01% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $244.11M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $241.33M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $239.23M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $244.19M | N/A | 2.23% | 2.23% | 2.23% |
| InflaRx N.V. (IFRX)vs › | $244.51M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $248.38M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.50M | N/A | N/A | N/A | N/A |
| BioAge Labs Inc. (BIOA)vs › | $236.82M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
